Anaemia is the most common physiologic disorder in women. Industrialized and semi-industrialized nations have a major problem, while resource-poor nations have a bigger problem. Public health issues like anaemia might affect pregnancy. 40% of fertile but non-pregnant women have low iron. Methods: The Rajkiya Mahila Chikitsalya Department of Obstetrics and Gynecology in Ajmer undertook an open label randomised clinical trial. The institute's ethics committee approved (IEC). All ladies were carefully assessed and recruited after meeting inclusion and exclusion criteria. A computer-generated random number table assigned 200 pregnant women aged 28–34 weeks to one of two groups in a 1:1 ratio. Results: The P value of 0.0001 shows that ferric carboxylates increase Hb significantly. The FCM group had significantly higher MCV levels than the IS group at 4 weeks (87.10±3.90 vs 91.51±2.25; p0.0001) and 8 weeks (94.55±2.89 vs 98.15±2.08). FCM had a considerably higher MCH value (31.2 pg) than IS (39.7 pg), P = 0.0001. RDW increased to 21.9 percent in the IS group and 22.4 percent in the FCM group at admission. At four weeks, intravenous iron preparation injections reduced RDW to 18.9% in the IS group and 19.78% in the FCM group. FCM rose more than Iron sucrose. 231 and 280 μg/L for IS and FCM groups. It was statistically significant. Both groups had 12 μg/L S. ferritin at admission. However, iv iron preparation elevated S. ferritin in both groups. FCM rose more than Iron sucrose at 4 and 8 weeks. 231 and 280 μg/L for IS and FCM groups. It was statistically significant. Conclusion: Anemia secretly hinders pregnancy, growth, and future generations. Anemia and its effects in pregnant women are being reduced. In pregnancy, compliance, and gastrointestinal adverse effects limit oral iron therapies. Parenteral iron therapy addresses compliance and tolerance.